# HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma

> **NCT02947152** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 9 (actual)

## Conditions studied

- Epithelial Ovarian Cancer
- Renal Cell Carcinoma

## Interventions

- **DRUG:** HKT288

## Key facts

- **NCT ID:** NCT02947152
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-01
- **Primary completion:** 2017-09-14
- **Final completion:** 2017-09-14
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02947152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02947152, "HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02947152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*